Sandeep Magoon, MD
Nephrology · Norfolk, VANPI 1962698720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,232 of the $203,924 with a category attached, or 85.4%. Bayer accounts for 60.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $73,642 and has fallen 78.5% since, to $15,830 in 2025. Among nephrology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $664.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$123K
- Calliditas Therapeutics US Inc.$72K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
- AstraZeneca$750
- Otsuka America Pharmaceutical, Inc.$400
- Travere Therapeutics, Inc.$185
- plus $1K from 16 others
What the payments were for
- Consulting fees$4,8142%
- Speaking & faculty fees$174,23285%
- Travel & lodging$18,8939%
- Food & beverage$5,6963%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 126 | $122,840 |
| Calliditas Therapeutics US Inc. | 74 | $72,377 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $5,986 |
| AstraZeneca(2 entities) | 26 | $750 |
| Otsuka America Pharmaceutical, Inc. | 11 | $400 |
| Travere Therapeutics, Inc. | 10 | $185 |
| Nxstage Medical, Inc. | 2 | $177 |
| Ardelyx, Inc. | 6 | $148 |
| Aurinia Pharma U.S., Inc. | 7 | $143 |
| Akebia Therapeutics Inc | 7 | $137 |
| Vifor Pharma, Inc. | 7 | $135 |
| Boehringer Ingelheim | 2 | $133 |
| Amgen(2 entities) | 6 | $123 |
| Bard Peripheral Vascular, Inc. | 1 | $117 |
| Scpharmaceuticals Inc. | 2 | $72 |
| Novartis | 3 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $50 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$120,842
- TARPEYO$71,136
- LOKELMA$120
- NXSTAGE SYSTEM ONE$116
- JARDIANCE$113
How this compares
$203,924 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 30 | $72,573 |
| KerendiaFinerenone | 37 | $32,671 |
| FarxigaDapagliflozin Propanediol | 35 | $28,318 |
| JardianceEmpagliflozin | 20 | $19,255 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $5,531 |
| Sevelamer Carbonate | 30 | $4,421 |
| Bumetanide | 22 | $1,655 |
| Hydralazine Hcl | 53 | $1,423 |
| Losartan Potassium | 105 | $1,229 |
| Furosemide | 98 | $651 |
| Calcitriol | 33 | $601 |
| Clonidine Hcl | 13 | $536 |
| Carvedilol | 52 | $535 |
| Nifedipine ErNifedipine | 23 | $451 |
| Amlodipine Besylate | 83 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $19 | $72,57330 claims |
| AstraZenecaFarxiga, Lokelma | $750 | $33,85047 claims |
| BayerKerendia | $122,840 | $32,67137 claims |
| Boehringer IngelheimJardiance | $133 | $19,25520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 298 nephrology providers in Virginia.
Other nephrology in Norfolk
- Thomas McCuneNorfolk$202K
- Ramin TolouianNorfolk$115K
- Wei ZhaoNorfolk$8K
- Harlan RustNorfolk$6K
- Maxim MirovskiNorfolk$4K
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Mahesh KrishnanMc Lean$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.